Startups
MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development.
Our vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease.
Our success in research and access & product management comes from our extensive partnership network of over 375 pharmaceutical, academic and endemic-country partners in 50 countries.
www.mmv.org
www.facebook.com/medicinesformalaria
www.twitter.com/medsformalaria
www.youtube.com/user/MMVmeds4malaria
http://plus.google.com/+mmvorgmedsformalaria
Our vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease.
Our success in research and access & product management comes from our extensive partnership network of over 375 pharmaceutical, academic and endemic-country partners in 50 countries.
www.mmv.org
www.facebook.com/medicinesformalaria
www.twitter.com/medsformalaria
www.youtube.com/user/MMVmeds4malaria
http://plus.google.com/+mmvorgmedsformalaria
Overview
Location
Switzerland, Geneva, Meyrin
Employees
51-200
Phone
+41 22 555 03 00
Founded date
1999
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 17, 2025 | Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tübingen | TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3 million1) in four R&D projects for the development of vaccine, drug, and... |
| May 9, 2024 | Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions | TOKYO, May 9, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria an... |
| Apr 25, 2024 | On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference | miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1% African authority on malaria diagnosis said "miLab is a potential game changer in accelerating access to parasi... |
| Jun 29, 2022 | Setting up an African drug discovery ecosystem: what will it take? | Setting up an African drug discovery ecosystem: what will it take? Image: Adobe stock Africa has great potential for drug discovery. The continent has natural resources, indigenous knowledge and human capacity. And it has the need: it bears... |
| Aug 20, 2021 | Program Update: The National Children’s Cancer Society and Fosun Pharma Partner to Help Patients in Guatemala | “We are more than grateful for everything you are doing to save the lives of our patients. And as always, all our admiration and gratitude for having managed to obtain this donation without sparing any effort until it is achieved,” said Sar... |
| Sep 6, 2011 | GSK expands antibacterial rights; adds malaria, TB to Anacor R&D pact | British pharma GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, started its partnership with Anacor in 2007 to develop anti-infectives against four targets. After a phase 1 trial, GSK last year exercised its o... |
| GSK expands antibacterial rights; adds malaria, TB to Anacor R&D pact | GlaxoSmithKline (NYSE:GSK) is bolstering the potential of its drug pipeline through an amended deal with drug partner Anacor Pharmaceuticals (NASDAQ:ANAC) that extends GSK’s rights to an anti-infective and adds new drug programs for tubercu... |
Reviews 0
FAQ about Medicines for Malaria Venture
When was Medicines for Malaria Venture founded?
Medicines for Malaria Venture was founded in 1999.
What has the press written about Medicines for Malaria Venture?
Parsers VC has collected 8 articles mentioning Medicines for Malaria Venture, among them “Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and...” (Jul 17, 2025) and “Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and E...” (May 9, 2024).
Is Medicines for Malaria Venture still active?
Yes, Medicines for Malaria Venture is active; its latest activity on Parsers VC dates from Oct 29, 2026.